DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
Open Access
- 20 August 2022
- journal article
- review article
- Published by Springer Nature in Military Medical Research
- Vol. 9 (1) , 1-15
Abstract
Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed effective in treating T2DM, the Food and Drug Administration (FDA) and some members of the scientific community have questioned the safety of these therapeutics relative to important cardiovascular endpoints. As a result, since 2008, the FDA has required all new drugs for glycemic control in T2DM patients to demonstrate cardiovascular safety. The present review article strives to assess the safety and benefits of incretin-based therapy, a new class of antidiabetic drug, on the health of patient cardiovascular systems. In the process, this review will also provide a physiological overview of the incretin system and how key components function in T2DM.Keywords
Funding Information
- National Natural Science Foundation of China (81974254, 31870906, 82170470)
This publication has 102 references indexed in Scilit:
- Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null MicePLOS ONE, 2013
- Glucagon-like peptide-1 analogues: An overviewIndian Journal of Endocrinology and Metabolism, 2013
- Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent MechanismDiabetes, 2013
- A Potential Role for Dendritic Cell/Macrophage-Expressing DPP4 in Obesity-Induced Visceral InflammationDiabetes, 2012
- Cardiovascular Biology of the Incretin SystemEndocrine Reviews, 2012
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific DeathNew England Journal of Medicine, 2011
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Beneficial effects of once‐daily liraglutide, a human glucagon‐like peptide‐1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetesDiabetic Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008